Sugi Predict

Sugi Predict / Compounds / SCHEMBL320082

SCHEMBL320082

SCHEMBL320082

c1cnn(C2CCCCO2)c1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CYP4F2 P78329 3/20 0.35
▸ CYP4A11 Q02928 3/20 0.35
▸ ALDH1A1 P00352 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ KDM5B Q9UGL1 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ RXRA P19793 1/20 0.32
▸ RXRB P28702 1/20 0.32
▸ RXRG P48443 1/20 0.32
▸ MEN1 O00255 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ ATR Q13535 1/20 0.31
▸ CD274 Q9NZQ7 1/20 0.31
▸ TRPC3 Q13507 1/20 0.30
▸ TRPC6 Q9Y210 1/20 0.30
▸ YTHDC1 Q96MU7 1/20 0.30
▸ HCAR2 Q8TDS4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27630999 0.94 ALDH1A1 (0.38) CYP4F2CYP4A11ALDH1A1LMNAPOLB
Boric Acid SCHEMBL28492132 0.93 CYP4F2 (0.34) CYP4F2CYP4A11ALDH1A1LMNAPOLB
SCHEMBL30483365 0.82 CYP4F2 (0.36) CYP4F2CYP4A11ALDH1A1LMNAPOLB
SCHEMBL30203333 0.82 ALDH1A1 (0.33) CYP4F2CYP4A11ALDH1A1LMNAPOLB
SCHEMBL3041585 0.81 CYP4F2 (0.40) CYP4F2CYP4A11ALDH1A1LMNAPOLB
SCHEMBL31298650 0.76 KDM5B (0.36) CYP4F2CYP4A11ALDH1A1LMNAPOLB
SCHEMBL5860682 0.74 CD274 (0.33) CYP4F2CYP4A11ALDH1A1LMNAPOLB
SCHEMBL28366438 0.74 LMNA (0.30) LMNA
SCHEMBL19253462 0.72 CYP4F2 (0.38) CYP4F2CYP4A11ALDH1A1LMNAPOLB
SCHEMBL26117393 0.72 MEN1 (0.31) ALDH1A1LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 341 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250075147-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS OSMO LABS, PBC 2025-03-06 — — US claimed
CN-119490480-A Isophenyl bridged alkynyl pyrazole pyridine derivative and preparation method and application thereof 北京工业大学 2025-02-21 — — CN claimed
CN-112608492-A Metal organic framework material of cobalt chain based on double-end pyrazole ligand, preparation and benzene adsorption application 北京工业大学 2021-04-06 — — CN claimed
WO-2021057256-A1 HETEROCYCLIC NITROGEN COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2021-04-01 — — WO claimed
EP-2847174-B1 PYRIMIDINONE CARBOXAMIDES AS INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL MYERS SQUIBB CO (US) 2017-05-17 — — EP claimed
EP-2844643-B1 PYRIMIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL MYERS SQUIBB CO (US) 2016-11-30 — — EP claimed
US-9394260-B2 Pyrimidinone carboxamide inhibitors of endothelial lipase BRISTOL-MYERS SQUIBB COMPANY (US) 2016-07-19 — — US claimed
US-20150361052-A1 PYRIMIDINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL-MYERS SQUIBB COMPANY 2015-12-17 — — US claimed
US-9199946-B2 Pyrimidinone carboxamide inhibitors of endothelial lipase BRISTOL-MYERS SQUIBB COMPANY (US) 2015-12-01 — — US claimed
EP-2847174-A1 PYRIMIDINONE CARBOXAMIDES AS INHIBITORS OF ENDOTHELIAL LIPASE Bristol-Myers Squibb Company (US) 2015-03-18 — — EP claimed
EP-2844643-A1 PYRIMIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE Bristol-Myers Squibb Company (US) 2015-03-11 — — EP claimed
US-20150065505-A1 PYRIMIDINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL-MYERS SQUIBB COMPANY (US) 2015-03-05 — — US claimed
WO-2013151923-A1 PYRIMIDINONE CARBOXAMIDES AS INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL-MYERS SQUIBB COMPANY (US) 2013-10-10 — — WO claimed
WO-2013151877-A1 PYRIMIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL-MYERS SQUIBB COMPANY (US) 2013-10-10 — — WO claimed
WO-2026090348-A1 THE USE OF SON OF SEVENLESS (SOS) INHIBITOR COMPOUNDS SUCH AS 7-SUBSTITUTED BENZOFURANS TO TREAT CANCER Mirati Therapeutics, Inc. (US) 2026-04-30 — — WO disclosed
US-20260008785-A1 MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF SCHRODINGER, LLC 2026-01-08 — — US disclosed
WO-2025202979-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR DERIVATIVES AS CBP AND/OR P300 DEGRADERS AURIGENE ONCOLOGY LIMITED (IN) 2025-10-02 — — WO disclosed
EP-0371947-A1 Substituted pyrazoles and their use as herbicides Monsanto Company (US) 1990-06-06 — — EP disclosed
EP-0370990-A1 Herbicidal substituted pyrazoles MONSANTO COMPANY (US) 1990-05-30 — — EP disclosed
EP-0295233-A2 Substituted 3-(4-nitrophenoxy)pyrazoles and their use as herbicides Monsanto Company (US) 1988-12-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260008785-A1 MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF CFTR, ABCC3, ABCD3 CYP4F2 1836/4885CYP4A11 2081/4885ALDH1A1 3672/4885
US-20150361052-A1 PYRIMIDINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE LIPG, LPL, PNLIP CYP4F2 754/4885CYP4A11 1271/4885ALDH1A1 299/4885
US-20150065505-A1 PYRIMIDINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE LIPG, LPL, PNLIP CYP4F2 777/4885CYP4A11 1322/4885ALDH1A1 410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.